{"task_id": "ce57d7dab7b72f97", "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf (Part 365/905)", "text": "s, where intensive therapies have poorer outcomes.\n\n--- Page 371 ---\n357\nHaematology\nThese are a heterogeneous group of disorders that manifest as marrow failure \nwith risk of life-threatening infection and bleeding (median survival varies from \n6 months to 6 years according to disease type). Mostly primary, but can develop \nsecondary to chemotherapy or radiotherapy. 30% transform to acute leukaemia. \nTests: Pancytopenia (p364), with \ue001reticulocyte count. Marrow cellularity is usu-\nally increased due to ineff ective haematopoiesis. Ring sideroblasts may also be \nseen in the marrow (\ufb01 g 8.9, p327).\nTreatment:\n  \n\u2022 Multiple transfusions of red cells or platelets as needed.\n  \n\u2022 Erythropoietin \u00b1 G-CSF (p352) may lower transfusion requirement.\n  \n\u2022 Allogeneic stem cell transplantation is one option (curative but often inappro-\npriate owing to age-related comorbidities\u2014most are >70yrs old).\n  \n\u2022 Low-intensity treatments that are not curative but may improve quality of life \nin symptomatic disease include thalidomide analogues (eg lenalidomide) or hy-\npomethylating agents (eg azacitidine and decitabine).\nMyelodysplastic syndromes (MDS, myelodysplasia)\nFig 8.50 Gum hypertrophy in AML.\nCourtesy of Prof. Christine Lawrence.\nFig 8.51 Auer rods (crystals of coalesced gran-\nules) found in AML myeloblast cells.\nCourtesy of Prof. Christine Lawrence.\nFig 8.52 AML with monoblasts and myelo blasts \non the peripheral blood \ufb01 lm.\nCourtesy of Prof. Christine Lawrence.\nFig 8.53 Marrow in AML: multiple monoblasts.\nCourtesy of Prof. Christine Lawrence.\nConsider four types of heterogeneity as we move through medical history: mor-\nphologic, immunophenotypic, cytogenetic, and molecular. Genomic technologies \nenable an ever more detailed molecular analysis of AML and this can be used to in-\nform prognosis and guide risk strati\ufb01 cation. Epigenetic and other pro\ufb01 ling reveals \nmore and more biomarkers, eg mutations in the genes encoding DNA (cytosine-5)-\nmethyltransferase 3A (DNMT3A).\nHeterogeneity in AML", "text_length": 2010, "metadata": {"source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf (Part 365/905)", "type": "chunk", "chunk_index": 364, "total_chunks": 905, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T17:59:52.793999", "document_uuid": "1c4b3c41-9a74-4d3d-ab11-d2a041c9641f", "filename": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf", "category": "medical_pdf", "section": "body", "year": 2017, "outdated": false, "document_id": "1c4b3c41-9a74-4d3d-ab11-d2a041c9641f"}, "created_at": "2025-12-11T17:59:52.795369", "status": "complete", "chunks_added": 2}